S&P 500   4,369.28 (+0.99%)
DOW   34,260.93 (+0.29%)
QQQ   345.39 (+1.26%)
AAPL   167.47 (+5.18%)
MSFT   302.28 (+0.81%)
FB   297.49 (+0.97%)
GOOGL   2,616.94 (+1.43%)
AMZN   2,812.83 (+0.72%)
TSLA   851.98 (+2.76%)
NVDA   223.17 (+1.70%)
BABA   112.34 (+0.49%)
NIO   20.78 (-1.56%)
AMD   103.87 (+1.24%)
CGC   7.11 (+3.80%)
MU   77.42 (-1.65%)
GE   89.95 (+0.06%)
T   24.47 (+1.45%)
F   19.40 (-0.77%)
DIS   135.37 (-0.04%)
AMC   14.35 (-1.17%)
PFE   53.98 (+1.14%)
ACB   3.85 (+1.58%)
BA   186.15 (-1.90%)
S&P 500   4,369.28 (+0.99%)
DOW   34,260.93 (+0.29%)
QQQ   345.39 (+1.26%)
AAPL   167.47 (+5.18%)
MSFT   302.28 (+0.81%)
FB   297.49 (+0.97%)
GOOGL   2,616.94 (+1.43%)
AMZN   2,812.83 (+0.72%)
TSLA   851.98 (+2.76%)
NVDA   223.17 (+1.70%)
BABA   112.34 (+0.49%)
NIO   20.78 (-1.56%)
AMD   103.87 (+1.24%)
CGC   7.11 (+3.80%)
MU   77.42 (-1.65%)
GE   89.95 (+0.06%)
T   24.47 (+1.45%)
F   19.40 (-0.77%)
DIS   135.37 (-0.04%)
AMC   14.35 (-1.17%)
PFE   53.98 (+1.14%)
ACB   3.85 (+1.58%)
BA   186.15 (-1.90%)
S&P 500   4,369.28 (+0.99%)
DOW   34,260.93 (+0.29%)
QQQ   345.39 (+1.26%)
AAPL   167.47 (+5.18%)
MSFT   302.28 (+0.81%)
FB   297.49 (+0.97%)
GOOGL   2,616.94 (+1.43%)
AMZN   2,812.83 (+0.72%)
TSLA   851.98 (+2.76%)
NVDA   223.17 (+1.70%)
BABA   112.34 (+0.49%)
NIO   20.78 (-1.56%)
AMD   103.87 (+1.24%)
CGC   7.11 (+3.80%)
MU   77.42 (-1.65%)
GE   89.95 (+0.06%)
T   24.47 (+1.45%)
F   19.40 (-0.77%)
DIS   135.37 (-0.04%)
AMC   14.35 (-1.17%)
PFE   53.98 (+1.14%)
ACB   3.85 (+1.58%)
BA   186.15 (-1.90%)
S&P 500   4,369.28 (+0.99%)
DOW   34,260.93 (+0.29%)
QQQ   345.39 (+1.26%)
AAPL   167.47 (+5.18%)
MSFT   302.28 (+0.81%)
FB   297.49 (+0.97%)
GOOGL   2,616.94 (+1.43%)
AMZN   2,812.83 (+0.72%)
TSLA   851.98 (+2.76%)
NVDA   223.17 (+1.70%)
BABA   112.34 (+0.49%)
NIO   20.78 (-1.56%)
AMD   103.87 (+1.24%)
CGC   7.11 (+3.80%)
MU   77.42 (-1.65%)
GE   89.95 (+0.06%)
T   24.47 (+1.45%)
F   19.40 (-0.77%)
DIS   135.37 (-0.04%)
AMC   14.35 (-1.17%)
PFE   53.98 (+1.14%)
ACB   3.85 (+1.58%)
BA   186.15 (-1.90%)
NASDAQ:VACC

Vaccitech Stock Forecast, Price & News

$9.61
0.00 (0.00%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.61
$9.61
50-Day Range
$8.98
$13.20
52-Week Range
$7.50
$17.99
Volume
423 shs
Average Volume
40,378 shs
Market Capitalization
$335.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive VACC News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.


About Vaccitech

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

Headlines

Vaccitech (NASDAQ:VACC) Stock Rating Reaffirmed by HC Wainwright
January 19, 2022 |  americanbankingnews.com
Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial
December 7, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VACC
Phone
N/A
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.82 million

Profitability

Net Income
$-17.71 million
Net Margins
-7,428.78%
Pretax Margin
-7,464.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$335.19 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/28/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

452nd out of 1,417 stocks

Pharmaceutical Preparations Industry

204th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Vaccitech (NASDAQ:VACC) Frequently Asked Questions

Is Vaccitech a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vaccitech stock.
View analyst ratings for Vaccitech
or view top-rated stocks.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.25. The business earned $0.02 million during the quarter, compared to analyst estimates of $1.65 million. Vaccitech had a negative trailing twelve-month return on equity of 38.44% and a negative net margin of 7,428.78%.
View Vaccitech's earnings history
.

What price target have analysts set for VACC?

4 equities research analysts have issued 1-year price targets for Vaccitech's shares. Their forecasts range from $22.00 to $28.00. On average, they expect Vaccitech's stock price to reach $24.33 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price.
View analysts' price targets for Vaccitech
or view top-rated stocks among Wall Street analysts.

Who are Vaccitech's key executives?

Vaccitech's management team includes the following people:
  • Mr. William J. Enright, CEO & Board Director (Age 58, Pay $572.88k)
  • Prof. Sarah Gilbert, Co-Founder
  • Prof. Adrian Hill, Co-Founder & Scientific Advisor
  • Mr. Georgy Egorov, Chief Financial Officer
  • Dr. Margaret Marshall M.D., Chief Medical Officer
  • Mr. Chris Ellis, Chief Operating Officer
  • Dr. Thomas George Evans, Chief Scientific Officer
  • Mr. Graham Griffiths, Chief Bus. Officer (LinkedIn Profile)
  • Ms. Elizabeth Eagling-Vose, Head of Clinical Operations
  • Bernie McDonald, Head of IP

When did Vaccitech IPO?

(VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Vaccitech's stock symbol?

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

How do I buy shares of Vaccitech?

Shares of VACC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccitech's stock price today?

One share of VACC stock can currently be purchased for approximately $9.61.

How much money does Vaccitech make?

Vaccitech has a market capitalization of $335.19 million and generates $4.82 million in revenue each year.

How many employees does Vaccitech have?

Vaccitech employs 2,021 workers across the globe.

What is Vaccitech's official website?

The official website for Vaccitech is www.vaccitech.co.uk.

Where are Vaccitech's headquarters?

How can I contact Vaccitech?

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company can be reached via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.